Neuropathic Pain Regimen in Stage 4 Chronic Kidney Disease
A 68-year-old man with type 2 diabetes and painful distal symmetric polyneuropathy has an eGFR of 26 mL/min/1.73 m² and A1c 8.4%. His medications are gabapentin 600 mg three times daily, duloxetine 60 mg daily, oxycodone 5 mg every 6 hours as needed (using 4–5 doses daily), lisinopril, and furosemide. Metformin was held. He reports dizziness, daytime somnolence, and one fall last month; pain is 7/10 with allodynia and reduced vibration sense. He has no suicidal ideation. He asks, "Can you just increase something? I can't keep living like this."
1. Prioritize the medication-related problems in this regimen and explain the renal and fall-risk reasoning.
Read the worked answer
The main problems are gabapentin accumulation with CKD, duloxetine use below the recommended renal threshold, opioid-related fall and sedation risk, and polypharmacy. Gabapentin is renally cleared; at eGFR 26, 600 mg three times daily can produce sedation, dizziness, and falls. Duloxetine is generally not recommended when CrCl is below 30 mL/min because of increased exposure. Oxycodone is preferable to morphine or codeine in CKD, but it still contributes to sedation and falls; as-needed use suggests inadequate nonopioid control. Lisinopril and furosemide can worsen orthostasis and renal function. The goal is to reduce cumulative central nervous system burden while still treating neuropathic pain.
2. Propose a revised pharmacologic plan with specific doses, titration intervals, and monitoring.
Read the worked answer
Taper duloxetine to 30 mg daily for 1–2 weeks, then stop, to avoid discontinuation symptoms. Reduce gabapentin to 100–200 mg at bedtime initially, with a maximum of about 200–700 mg/day in divided doses for eGFR 15–29; titrate every 1–2 weeks based on sedation and pain. Discontinue oxycodone if possible; if needed short term, use 2.5 mg every 8 hours as needed with a bowel regimen and naloxone. Add topical lidocaine 5% patches to the feet for up to 12 hours per day and consider capsaicin. Avoid tramadol and codeine. Reassess orthostasis, falls, sedation, and renal function at each visit.
3. How would you counsel the patient and document shared decision-making?
Read the worked answer
Explain that the current regimen is likely causing more harm than benefit and that adding another sedating drug is not safer. Set goals of improved function, sleep, and fall reduction rather than zero pain. Discuss off-label use, expected titration, and withdrawal effects. Provide naloxone and education. Document shared decision-making: risks of CKD, falls, and sedation; alternatives; patient preferences; and follow-up in 2 weeks. Coordinate with nephrology and pharmacy. State clearly that the plan prioritizes safety while continuing to treat neuropathic pain.